Comments
Loading...

AtriCure Analyst Ratings

ATRCNASDAQ
Logo brought to you by Benzinga Data
Consensus Rating1
Buy
Highest Price Target1
$60.00
Lowest Price Target1
$40.00
Consensus Price Target1
$50.55

AtriCure Analyst Ratings and Price Targets | NASDAQ:ATRC | Benzinga

AtriCure Inc has a consensus price target of $50.55 based on the ratings of 11 analysts. The high is $60 issued by JMP Securities on April 30, 2025. The low is $40 issued by JP Morgan on October 30, 2024. The 3 most-recent analyst ratings were released by UBS, JMP Securities, and Needham on April 30, 2025, respectively. With an average price target of $54 between UBS, JMP Securities, and Needham, there's an implied 58.68% upside for AtriCure Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Dec 24
2
Jan
6
Feb
4
Mar
2
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

UBS
JMP Securities
Needham
Citizens Capital Markets
Canaccord Genuity

1calculated from analyst ratings

Analyst Ratings for AtriCure

Buy NowGet Alert
04/30/2025Buy Now70.44%UBS
Danielle Antalffy65%
$60 → $58MaintainsBuyGet Alert
04/30/2025Buy Now76.32%JMP Securities
Daniel Stauder51%
$60 → $60ReiteratesMarket Outperform → Market OutperformGet Alert
04/30/2025Buy Now29.3%Needham
Mike Matson63%
$51 → $44MaintainsBuyGet Alert
04/02/2025Buy Now76.32%Citizens Capital Markets
Daniel Stauder51%
$60 → $60ReiteratesMarket Outperform → Market OutperformGet Alert
03/28/2025Buy Now52.81%Canaccord Genuity
William Plovanic60%
$66 → $52MaintainsBuyGet Alert
03/27/2025Buy Now35.17%JP Morgan
Lilia-Celine Lozada29%
$51 → $46MaintainsOverweightGet Alert
03/27/2025Buy Now49.87%Needham
Mike Matson63%
$51 → $51ReiteratesBuy → BuyGet Alert
03/21/2025Buy Now49.87%Needham
Mike Matson63%
$51 → $51ReiteratesBuy → BuyGet Alert
02/13/2025Buy Now32.24%Oppenheimer
Suraj Kalia59%
$36 → $45MaintainsOutperformGet Alert
02/13/2025Buy Now46.93%Piper Sandler
Matt O'Brien56%
$40 → $50MaintainsOverweightGet Alert
02/13/2025Buy Now76.32%JMP Securities
Daniel Stauder51%
$60 → $60ReiteratesMarket Outperform → Market OutperformGet Alert
02/13/2025Buy Now41.05%Stifel
Rick Wise75%
$36 → $48MaintainsBuyGet Alert
02/13/2025Buy Now49.87%Needham
Mike Matson63%
$51 → $51ReiteratesBuy → BuyGet Alert
02/13/2025Buy Now93.95%Canaccord Genuity
William Plovanic60%
$61 → $66MaintainsBuyGet Alert
02/11/2025Buy Now49.87%JP Morgan
Lilia-Celine Lozada29%
$40 → $51MaintainsOverweightGet Alert
02/10/2025Buy Now76.32%JMP Securities
Daniel Stauder51%
$60 → $60ReiteratesMarket Outperform → Market OutperformGet Alert
01/22/2025Buy Now49.87%Needham
Mike Matson63%
$40 → $51MaintainsBuyGet Alert
01/13/2025Buy Now17.54%Needham
Mike Matson63%
$40 → $40ReiteratesBuy → BuyGet Alert
12/17/2024Buy Now17.54%JP Morgan
Lilia-Celine Lozada29%
→ $40Assumes → OverweightGet Alert
12/09/2024Buy Now79.25%Canaccord Genuity
William Plovanic60%
$53 → $61MaintainsBuyGet Alert
10/30/2024Buy Now55.74%Canaccord Genuity
William Plovanic60%
$49 → $53MaintainsBuyGet Alert
10/30/2024Buy Now5.79%Oppenheimer
Suraj Kalia59%
$32 → $36MaintainsOutperformGet Alert
10/30/2024Buy Now17.54%JP Morgan
Robbie Marcus63%
$30 → $40MaintainsOverweightGet Alert
10/30/2024Buy Now17.54%UBS
Danielle Antalffy65%
$35 → $40MaintainsBuyGet Alert
10/30/2024Buy Now17.54%Needham
Mike Matson63%
$34 → $40MaintainsBuyGet Alert
07/31/2024Buy Now55.74%BTIG
Marie Thibault64%
$58 → $53MaintainsBuyGet Alert
07/31/2024Buy Now-11.84%JP Morgan
Robbie Marcus63%
$34 → $30MaintainsOverweightGet Alert
07/31/2024Buy Now-23.6%Stifel
Rick Wise75%
$30 → $26MaintainsBuyGet Alert
07/31/2024Buy Now17.54%Piper Sandler
Matt O'Brien56%
$65 → $40MaintainsOverweightGet Alert
07/31/2024Buy Now-0.09%Needham
Mike Matson63%
$40 → $34MaintainsBuyGet Alert
07/08/2024Buy Now17.54%Needham
Mike Matson63%
$40 → $40ReiteratesBuy → BuyGet Alert
05/02/2024Buy Now43.99%Canaccord Genuity
William Plovanic60%
$57 → $49MaintainsBuyGet Alert
05/02/2024Buy Now-0.09%JP Morgan
Robbie Marcus63%
$42 → $34MaintainsOverweightGet Alert
05/02/2024Buy Now17.54%Needham
Mike Matson63%
$46 → $40MaintainsBuyGet Alert
04/23/2024Buy Now-5.97%Oppenheimer
Suraj Kalia59%
→ $32UpgradePerform → OutperformGet Alert
04/10/2024Buy Now35.17%Needham
Mike Matson63%
$46 → $46ReiteratesBuy → BuyGet Alert
02/16/2024Buy Now70.44%UBS
Danielle Antalffy65%
$57 → $58MaintainsBuyGet Alert
02/16/2024Buy Now23.42%Stifel
Rick Wise75%
$50 → $42MaintainsBuyGet Alert
02/16/2024Buy Now35.17%Needham
Mike Matson63%
$44 → $46MaintainsBuyGet Alert
01/22/2024Buy Now67.5%UBS
Danielle Antalffy65%
$56 → $57MaintainsBuyGet Alert
01/04/2024Buy Now29.3%Needham
Mike Matson63%
$49 → $44MaintainsBuyGet Alert
11/29/2023Buy Now76.32%JMP Securities
Daniel Stauder51%
→ $60ReiteratesMarket Outperform → Market OutperformGet Alert
11/29/2023Buy Now43.99%Needham
Mike Matson63%
→ $49ReiteratesBuy → BuyGet Alert
11/02/2023Buy Now46.93%JP Morgan
Robbie Marcus63%
$60 → $50MaintainsOverweightGet Alert
11/02/2023Buy Now43.99%Needham
Mike Matson63%
$68 → $49MaintainsBuyGet Alert
10/23/2023Buy Now76.32%JMP Securities
Daniel Stauder51%
→ $60Initiates → Market OutperformGet Alert
09/29/2023Buy Now64.56%UBS
Danielle Antalffy65%
→ $56Initiates → BuyGet Alert
07/26/2023Buy Now99.82%Needham
Mike Matson63%
$60 → $68MaintainsBuyGet Alert
06/02/2023Buy Now76.32%Needham
Mike Matson63%
→ $60ReiteratesBuy → BuyGet Alert
05/03/2023Buy Now76.32%Needham
Mike Matson63%
$58 → $60MaintainsBuyGet Alert
04/17/2023Buy Now70.44%Needham
Mike Matson63%
→ $58MaintainsBuyGet Alert
02/22/2023Buy Now61.62%BTIG
Marie Thibault64%
$65 → $55MaintainsBuyGet Alert
02/22/2023Buy Now41.05%Stifel
Rick Wise75%
$55 → $48MaintainsBuyGet Alert
02/22/2023Buy Now117.46%Canaccord Genuity
William Plovanic60%
$81 → $74MaintainsBuyGet Alert
02/22/2023Buy Now70.44%Needham
Mike Matson63%
→ $58Reiterates → BuyGet Alert
02/06/2023Buy Now138.03%Canaccord Genuity
William Plovanic60%
$67 → $81MaintainsBuyGet Alert
12/19/2022Buy Now70.44%Needham
Mike Matson63%
$55 → $58MaintainsBuyGet Alert
11/02/2022Buy Now91.01%Canaccord Genuity
William Plovanic60%
$72 → $65MaintainsBuyGet Alert
11/02/2022Buy Now61.62%Needham
Mike Matson63%
$65 → $55MaintainsBuyGet Alert
10/17/2022Buy Now108.64%BTIG
Marie Thibault64%
$75 → $71MaintainsBuyGet Alert
08/03/2022Buy Now61.62%Piper Sandler
Matt O'Brien56%
$90 → $55MaintainsOverweightGet Alert
08/03/2022Buy Now91.01%Needham
Mike Matson63%
$55 → $65MaintainsBuyGet Alert
07/18/2022Buy Now46.93%Stifel
Rick Wise75%
$70 → $50MaintainsBuyGet Alert
06/28/2022Buy Now61.62%Needham
Mike Matson63%
$67 → $55MaintainsBuyGet Alert
06/24/2022Buy Now120.39%BTIG
Marie Thibault64%
$94 → $75MaintainsBuyGet Alert

FAQ

Q

What is the target price for AtriCure (ATRC) stock?

A

The latest price target for AtriCure (NASDAQ:ATRC) was reported by UBS on April 30, 2025. The analyst firm set a price target for $58.00 expecting ATRC to rise to within 12 months (a possible 70.44% upside). 31 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for AtriCure (ATRC)?

A

The latest analyst rating for AtriCure (NASDAQ:ATRC) was provided by UBS, and AtriCure maintained their buy rating.

Q

When was the last upgrade for AtriCure (ATRC)?

A

The last upgrade for AtriCure Inc happened on April 23, 2024 when Oppenheimer raised their price target to $32. Oppenheimer previously had a perform for AtriCure Inc.

Q

When was the last downgrade for AtriCure (ATRC)?

A

There is no last downgrade for AtriCure.

Q

When is the next analyst rating going to be posted or updated for AtriCure (ATRC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AtriCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AtriCure was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.

Q

Is the Analyst Rating AtriCure (ATRC) correct?

A

While ratings are subjective and will change, the latest AtriCure (ATRC) rating was a maintained with a price target of $60.00 to $58.00. The current price AtriCure (ATRC) is trading at is $34.03, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch